Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________________________ Form 10-K _____________________________________________________________________________________________ ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q3 2022 Earnings Conference Call October 27, 2022 8:30 AM ET Company Participants Christine Lindenboom - Senior Vice President, Investor Relations and Corporate Communications Yvonne Greenstreet - Chief Executive Officer Tolga Tanguler - Chief Commercial Officer Akshay Vaishnaw - President Jeff Poulton - Chief Financial Officer Conference Call Participants Maury Raycroft - Jefferies Salveen Richter - Goldman Sachs Tazeen Ahmad - Bank of America Eliana Merle - UBS ...

Financial Performance - Alnylam's Q2 2022 net product revenues reached $214 million, a 33% increase compared to $161 million in Q2 2021[48] - At constant exchange rates (CER), total net product revenue growth was 40%[48] - ONPATTRO global Q2 2022 net product revenues were $153 million[17] - GIVLAARI global Q2 2022 net product revenues were $52 million[23] - OXLUMO global Q2 2022 net product revenues were $9 million[27] Product Growth - ONPATTRO experienced a 35% year-over-year (YoY) global growth and 12% quarter-over-quarter (QoQ) growth[19] - GIVLAARI showed a 47% YoY global growth and 28% QoQ growth[25] - OXLUMO had a -9% YoY global growth but a 2% QoQ growth[29] 2022 Financial Guidance - The company reiterated its 2022 net product revenue guidance of $870 million to $930 million[49] - Net revenues from collaborations and royalties are expected to be between $175 million and $225 million[49] - Non-GAAP combined R&D and SG&A expenses are projected to be $1390 million to $1450 million[49]

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q2 2022 Earnings Conference Call July 28, 2022 8:30 AM ET Company Participants Christine Lindenboom – Senior Vice President-Investor Relations and Corporate Communications Yvonne Greenstreet – Chief Executive Officer Tolga Tanguler – Chief Commercial Officer Akshay Vaishnaw – President Jeff Poulton – Chief Financial Officer Conference Call Participants Paul Matteis – Stifel David Lebowitz – Citi Salveen Richter – Goldman Sachs Ritu Baral – Cowen Tazeen Ahmad – Ban ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2022 Earnings Conference Call April 28, 2022 8:30 AM ET Company Participants Christine Lindenboom - Senior Vice President of Investor Relations and Corporate Communications Yvonne Greenstreet - Chief Executive Officer Tolga Tanguler - Chief Commercial Officer Pushkal Garg - Chief Medical Officer Jeff Poulton - Chief Financial Officer Conference Call Participants David Lebowitz - Citigroup Maury Raycroft - Jefferies Salveen Richter - Goldman Sachs Paul Matteis - ...